Skip to main
PRCT

PRCT Stock Forecast & Price Target

PRCT Analyst Ratings

Based on 10 analyst ratings
Hold
Strong Buy 10%
Buy 40%
Hold 40%
Sell 10%
Strong Sell 0%

Bulls say

PROCEPT BioRobotics is well-positioned for long-term success with its transformative solutions in urology and its focus on BPH. Upside risks to the company include better procedure volumes, higher average selling prices, and potential acquisition. On the other hand, potential challenges could arise from slower procedure growth or reimbursement changes for the competing PAE treatment. Despite these uncertainties, the company has reiterated its strong financial outlook for the year, with revenue growth and improved margins expected. Additionally, recent capital placements signal high demand for the company's technology, and its stock currently undervalues future growth potential, making it a sound investment choice.

Bears say

PROCEPT BioRobotics is facing a slowing procedure growth, primarily due to increased competition and restructuring within the company's sales force. While new leadership has put forth initiatives to increase system utilization, it remains to be seen if they will be successful and if so, how long it will take to have an impact. With a significant increase in competition and potential headwinds from rising adoption of a competing procedure, there are concerns about the company's ability to meet its procedure growth targets, leading to a negative outlook on the stock.

PRCT has been analyzed by 10 analysts, with a consensus rating of Hold. 10% of analysts recommend a Strong Buy, 40% recommend Buy, 40% suggest Holding, 10% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of PROCEPT BioRobotics Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About PROCEPT BioRobotics Corp (PRCT) Forecast

Analysts have given PRCT a Hold based on their latest research and market trends.

According to 10 analysts, PRCT has a Hold consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $28.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $28.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

PROCEPT BioRobotics Corp (PRCT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.